Andreas Viardot

10PUBLICATIONS
39CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 06, 2026
Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

|Feb 08, 2025
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.

Fabian Lang, Andreas Voss, Guido Kobbe

|Sep 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).

Olivier Tournilhac, Bettina Altmann, Birte Friedrichs

|May 03, 2022
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.

Deborah A Katz, Joan D Morris, Michael P Chu

|Apr 30, 2022
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.

Sarah Bailly, Guillaume Cartron, Sridhar Chaganti

|Feb 23, 2022
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature.

Alexander Grunenberg, Elisa Sala, Silke Kapp-Schwoerer

Pageof 2

Frequent Collaborators

2 joint publications

Guillaume Cartron

2 joint publications

Juan-Manuel Sancho

1 joint publications

Dominic Kaddu-Mulindwa

1 joint publications

Sarah Bailly